Cargando…

Association between biochemical control and comorbidities in patients with acromegaly: an Italian longitudinal retrospective chart review study

PURPOSE: Achieving biochemical control (normalization of insulin-like growth factor-1 [IGF-1] and growth hormone [GH]) is a key goal in acromegaly management. However, IGF-1 and GH fluctuate over time. The true potential impact of time-varying biochemical control status on comorbidities is unclear a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colao, A., Grasso, L. F. S., Di Cera, M., Thompson-Leduc, P., Cheng, W. Y., Cheung, H. C., Duh, M. S., Neary, M. P., Pedroncelli, A. M., Maamari, R., Pivonello, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067716/ https://www.ncbi.nlm.nih.gov/pubmed/31741320 http://dx.doi.org/10.1007/s40618-019-01138-y

Ejemplares similares

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
por: Giustina, A., et al.
Publicado: (2014)

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

The association between biochemical control and cardiovascular risk factors in acromegaly
por: Carmichael, John D., et al.
Publicado: (2017)

Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience
por: Pirchio, R., et al.
Publicado: (2023)

Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
por: Gadelha, Mônica R, et al.
Publicado: (2020)

Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY
por: Grottoli, S., et al.
Publicado: (2022)

Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study
por: Colao, Annamaria, et al.
Publicado: (2020)

The Biochemical Diagnosis of Acromegaly
por: Akirov, Amit, et al.
Publicado: (2021)

Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases
por: Burton, Tanya, et al.
Publicado: (2012)

The Pharmacological Burden of Comorbidities in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2021)

Long-term treatment outcomes of acromegaly patients presenting biochemically-uncontrolled at a tertiary pituitary center
por: Carmichael, John D., et al.
Publicado: (2017)

SAT-LB60 Discordant Biological Parameters of Remission in Acromegaly Do Not Increase the Risk of Hypertension or Diabetes: A Study With the Liege Acromegaly Survey Database
por: Amodru, Vincent, et al.
Publicado: (2020)

Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters
por: Geraedts, Victor J., et al.
Publicado: (2017)

Prevalence of Comorbidities among Patients with Acromegaly
por: Khan, Sajjad Ali, et al.
Publicado: (2021)

Complications and Comorbidities of Acromegaly—Retrospective Study in Polish Center
por: Rolla, Małgorzata, et al.
Publicado: (2021)

MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population
por: Whittington, Melanie D, et al.
Publicado: (2020)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study
por: Gadelha, Mônica, et al.
Publicado: (2019)

Editorial: Health-Related Complications of Acromegaly
por: Bolanowski, Marek, et al.
Publicado: (2020)

Challenges in the diagnosis and management of acromegaly: a focus on comorbidities
por: Abreu, Alin, et al.
Publicado: (2016)

Discordant biochemical parameters of acromegaly remission do not influence the prevalence or aggressiveness of metabolic comorbidities: a single-center study
por: Romanisio, Martina, et al.
Publicado: (2023)

Hypertension in Acromegaly in Relationship to Biochemical Control and Mortality: Global ACROSTUDY Outcomes
por: Vila, Greisa, et al.
Publicado: (2020)

Acromegaly and Vaccination
por: Leverson, M. R.
Publicado: (1899)

Durable biochemical response and safety with oral octreotide capsules in acromegaly
por: Samson, Susan L, et al.
Publicado: (2022)

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022)

Prevalence of comorbidities and associated factors in acromegaly patients in the Turkish population
por: CAN, Mustafa, et al.
Publicado: (2021)

The dopaminergic control of Cushing’s syndrome
por: Pivonello, R., et al.
Publicado: (2022)

Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database
por: Petrossians, Patrick, et al.
Publicado: (2017)

Bringing Cardiovascular Comorbidities in Acromegaly to an Update. How Should We Diagnose and Manage Them?
por: Ramos-Leví, Ana M., et al.
Publicado: (2019)

Incidence and prevalence of acromegaly in a large US health plan database
por: Burton, Tanya, et al.
Publicado: (2016)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

The Relationship between the Burden of Acromegaly, Associated Comorbidities, Complications and Disease Status
por: Elbaum, Michał, et al.
Publicado: (2023)

The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome
por: Klibanski, Anne, et al.
Publicado: (2009)

Bone biochemical markers in acromegaly: An association with disease activity and gonadal status
por: Piskinpasa, Mehmet Emin, et al.
Publicado: (2022)

Changes in Quality of Life After Long-Term Biochemical Control of Acromegaly
por: Kimball, Allison, et al.
Publicado: (2021)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
por: Bronstein, Marcello D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_n5epsad70a6ilmv7i0jailmk39